Table 2.
Glucometric parameters at baseline and follow-up virtual visits in all patients and in those grouped in accordance with the insulin delivery method and glucose monitoring system (N=166).
| Patient groups | Parameters | P valuea | ||
|
|
Baseline visit | Follow-up visit |
|
|
| Time in range (%), mean (SD) | ||||
|
|
All patients (n=166) | 62 (18) | 65 (16) | .02 |
|
|
CSIIb+CGMc (n=122) | 63 (17) | 65 (17) | .24 |
|
|
MDId+CGM (n=33) | 62 (19) | 64 (17) | .19 |
|
|
CSII or MDI+SMBGe (n=11) | 55 (17) | 66 (13) | .01 |
| Time below range (%), mean (SD) | ||||
|
|
All patients (n=166) | 3.5 (4.1) | 3.4 (3.8) | .58 |
|
|
CSII+CGM (n=122) | 3.2 (4.0) | 3.1 (3.7) | .86 |
|
|
MDI+CGM (n=33) | 4.4 (4.3) | 3.7 (3.3) | .34 |
|
|
CSII or MDI+SMBG (n=11) | 4.7 (4.0) | 5.8 (5.0) | .33 |
| Time above range (%), mean (SD) | ||||
|
|
All patients (n=166) | 34 (18) | 32 (18) | .08 |
|
|
CSII+CGM (n=122) | 34 (18) | 33 (18) | .40 |
|
|
MDI+CGM (n=33) | 33 (21) | 32 (18) | .52 |
|
|
CSII or MDI+SMBG (n=11) | 40 (18) | 28 (15) | .03 |
| Mean daily glucose (mg/dL), mean (SD) | ||||
|
|
All patients (n=166) | 163 (29) | 159 (25) | .25 |
|
|
CSII+CGM (n=122) | 162 (25) | 161 (24) | .90 |
|
|
MDI+CGM (n=33) | 162 (37) | 157 (26) | .17 |
|
|
CSII or MDI+SMBG (n=11) | 176 (49) | 150 (25) | .04 |
| Coefficient of variation (%), mean (SD) | ||||
|
|
All patients (n=166) | 34 (6) | 34 (7) | .32 |
|
|
CSII+CGM (n=122) | 34 (6) | 33 (7) | .93 |
|
|
MDI+CGM (n=33) | 36 (7) | 35 (7) | .55 |
|
|
CSII or MDI+SMBG (n=11) | 36 (8) | 42 (9) | .04 |
| Glucose management indicator (%), mean (SD) | ||||
|
|
All patients (n=166) | 7.2 (0.7) | 7.1 (0.6) | .23 |
|
|
CSII+CGM (n=122) | 7.2 (0.6) | 7.1 (0.6) | .90 |
|
|
MDI+CGM (n=33) | 7.2 (0.8) | 7.0 (0.6) | .12 |
|
|
CSII or MDI+SMBG (n=11) | 7.5 (1.1) | 6.9 (0.6) | .04 |
aSignificant P values are shown in italics.
bCSII: continuous subcutaneous insulin infusion.
cCGM: continuous glucose monitoring.
dMDI: multiple daily insulin injection.
eSMBG: self-monitoring blood glucose.